Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -115.75% is 17% below its 5-year average of -98.90%, around the middle of its 5-year range (-217.41%–36.51%).
9.13% above its 12-month average of -127.38%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -8.71%.
RETURN ON ASSETS (ROA)
-115.75%
RETURN ON ASSETS (ROA) AVG TTM
-127.38%
RETURN ON ASSETS (ROA) AVG 3Y
-59.19%
RETURN ON ASSETS (ROA) AVG 5Y
-98.90%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+9.13%
CURRENT VS 3Y AVG
-95.55%
CURRENT VS 5Y AVG
-17.03%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-259.03%
vs the sector median at left
Opus Genetics, Inc.
Market Cap
$365.88M
Return on Assets (ROA)
-115.75%
TTM Avg
-127.38%
3Y Avg
-59.19%
5Y Avg
-98.90%
Market Cap
$359.35M
Return on Assets (ROA)
-4.29%
TTM Avg
-7.44%
3Y Avg
-40.66%
5Y Avg
-49.61%
Market Cap
$357.45M
Return on Assets (ROA)
6.92%
TTM Avg
7.42%
3Y Avg
10.30%
5Y Avg
25.30%
Market Cap
$356.90M
Return on Assets (ROA)
-24.64%
TTM Avg
-45.98%
3Y Avg
-40.55%
5Y Avg
-44.33%
Market Cap
$357.11M
Return on Assets (ROA)
-21.30%
TTM Avg
-29.99%
3Y Avg
-30.23%
5Y Avg
-24.37%
Market Cap
$356.88M
Return on Assets (ROA)
-65.87%
TTM Avg
-110.74%
3Y Avg
-99.78%
5Y Avg
-89.00%
Market Cap
$356.54M
Return on Assets (ROA)
7.10%
TTM Avg
6.66%
3Y Avg
6.31%
5Y Avg
10.17%
Market Cap
$376.22M
Return on Assets (ROA)
-24.06%
TTM Avg
-44.34%
3Y Avg
-68.40%
5Y Avg
-50.78%
Market Cap
$377.23M
Return on Assets (ROA)
-69.44%
TTM Avg
-48.37%
3Y Avg
-55.05%
5Y Avg
-50.20%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Opus Genetics, Inc. (IRD) | $365.88M | -115.75% | -127.38% | -59.19% | -98.90% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.35M | -4.29% | -7.44% | -40.66% | -49.61% |
| Embecta Corp. (EMBC)vs › | $357.45M | 6.92% | 7.42% | 10.30% | 25.30% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $356.90M | -24.64% | -45.98% | -40.55% | -44.33% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $357.11M | -21.30% | -29.99% | -30.23% | -24.37% |
| Ocugen, Inc. (OCGN)vs › | $356.88M | -65.87% | -110.74% | -99.78% | -89.00% |
| Viemed Healthcare, Inc. (VMD)vs › | $356.54M | 7.10% | 6.66% | 6.31% | 10.17% |
| Canopy Growth Corporation (CGC)vs › | $376.22M | -24.06% | -44.34% | -68.40% | -50.78% |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $377.23M | -69.44% | -48.37% | -55.05% | -50.20% |
| YD Bio Limited Ordinary Shares (YDES)vs › | $378.24M | -29.57% | -40.44% | -13.88% | -8.39% |
ROA
-115.8%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -98.70% |
| 2024-12-31 | -156.07% |
| 2023-12-31 | -18.51% |
| 2022-12-31 | 36.51% |
| 2021-12-31 | -217.41% |
| 2020-12-31 | -139.24% |
| 2019-12-31 | -345.80% |
